Humacyte, Inc.
HUMA
$1.47
-$0.03-2.00%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | -196.22% | 286.91% | 46.58% | 30.82% | -77.65% |
Total Depreciation and Amortization | 1.53% | 1.33% | -0.22% | 1.85% | -0.67% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 117.97% | -1,113.75% | -144.67% | -62.52% | 298.15% |
Change in Net Operating Assets | 85.38% | -282.41% | -173.26% | -15.87% | 187.08% |
Cash from Operations | 7.65% | -7.62% | -16.02% | -7.59% | 22.15% |
Capital Expenditure | -149.12% | -261.90% | 93.25% | -407.61% | 52.94% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -- | -- | -- | -- | -- |
Cash from Investing | -149.12% | -261.90% | 93.25% | -407.61% | 52.94% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -5.82% | -2.08% | -2.12% | -2.33% | -6.80% |
Issuance of Common Stock | -93.18% | -5.45% | 10,033.74% | -37.10% | -98.19% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | 49.75% | 266.07% | -103.05% |
Cash from Financing | -95.37% | -8.37% | 5,907.77% | 281.80% | -100.74% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -238.55% | -26.50% | 205.98% | -4.79% | -162.59% |